3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Breast Neoplasms
2
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
Nivolumab
3
Cyclophosphamide
3
pembrolizumab
2
fludarabine phosphate
2
fludarabine
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Fluorodeoxyglucose F18
2
Everolimus
2
Carboplatin
2
tislelizumab
1
taxane
1
surufatinib
1
romidepsin
1
repotrectinib
1
pralsetinib
1
olaparib
1
liposomal doxorubicin
1
entrectinib
1
cabozantinib
1
atezolizumab
1
alectinib
1
aldesleukin
1
Vinorelbine
1
Temozolomide
1
Specimen Handling
1
RRx-001
1
Quality of Life
1
Pemetrexed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
entrectinib
×
Thoracic
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA